Xenetic Biosciences reports FY2023 net loss of $4.1M; cash at $9.0M

Xenetic Biosciences, Inc.

Net loss of $4.1M for year ended Dec 31, 2023; R&D expenses down 26.7% to $3.5M.
Royalty payments from Takeda sublicense rose 48.8% to $2.5M in 2023.
Cash and cash equivalents of $9.0M at year-end to fund operations.
Advancing DNase-based oncology platform targeting pancreatic carcinoma toward Phase 1 trial.
Entered research funding and material transfer agreement with University of Virginia.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xenetic Biosciences, Inc. reported the year ended December 31, 2023 results: net income approximately $4.1 million.

Period: the year ended December 31, 2023
Net income: approximately $4.1 million
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2023 was approximately $4.1 million.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenetic Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-001606

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.